Role of Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation
Role of Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation
复制标题
DOI：
10.1177/1526924816664083
复制
发表时间：
2016-12-01
影响因子：
0.8
通讯作者：
Azoulay, Daniel
中科院分区：
文献类型：
--
作者：
de'Angelis, Nicola;Landi, Filippo;Azoulay, Daniel
背景：肝移植(LT)后肝细胞癌(HCC)复发的管理是具有挑战性的，尤其是在无法通过手术或栓塞治疗的情况下。目的：本研究旨在比较接受索拉非尼或最佳支持治疗(BSC)的肝移植患者对无法达到治疗目的的肝癌复发的存活率。设计：这是一项对前瞻性维护的数据库进行的回溯性比较研究。研究对象：肝移植后无法治愈的肝癌复发患者，2007年前接受BSC(n=18)治疗，之后接受索拉非尼治疗(n=15)。结果：移植时和肝细胞癌复发时的人口学特征没有组间差异。在肝移植病理上，81.2%的患者符合米兰标准，53.1%的患者表现为微血管侵犯。肝移植后17.8个月(标准差：14.5)诊断为肝细胞癌复发，其中17例(53.1%)患者出现早期复发(
Context: The management of hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT) is challenging, especially if it is not treatable by surgery or embolization. Objectives: The present study aims to compare the survival rates of liver transplanted patients receiving sorafenib or best supportive care (BSC) for HCC recurrence not amenable to curative intent treatments. Design: This is a retrospective comparative study on a prospectively maintained database. Participants: Liver transplanted patients with untreatable HCC recurrence receiving BSC (n = 18) until 2007 or sorafenib (n = 15) thereafter were compared. Results: No group difference was observed for demographic characteristics at the time of transplantation and at the time of HCC recurrence. On the explant pathology of the native liver, 81.2% patients were classified within the Milan criteria, and 53.1% presented with microvascular invasion. Hepatocellular carcinoma recurrence was diagnosed 17.8 months (standard deviation: 14.5) after LT, with 17 (53.1%) patients presenting with early recurrence (